Lykke Advice aims to engage in the EU political sphere and to provide clients and readers with a unique view on specific topics, policies and debates related to EU public affairs. Occasionally, we also invite external authors to present their expert opinion on our blog.
Rare diseases impact between 30 and 36 million people in the EU. To foster research, pooling scarce resources spread across the EU is essential.
The Covid-19 pandemic in 2020 triggered an epidemic of another kind: mental health issues. This was due to many reasons from social isolation measures to
In early 2023, the European Parliament launched the Public Health Subcommittee (SANT). The newly established body became operational in April, when it presented its work
Various actors have voiced growing concerns about the existing blood and plasma legislation. The most prominent questions revolve around supply and demand, spurred by an
Introduction HERA is the EU’s Health Emergency Preparedness and Response Authority, on which we already published an article on 21 September last year. Please click
From 1 January until 30 June 2022, the Council of the EU will be presided by France. This article will provide an overview of France’s
In February this year, the European Commission introduced ‘Europe’s Beating Cancer Plan’. It was presented as one of the main priorities of the Von der
In last week’s analysis of the upcoming revision of the General Pharmaceuticals Legislation, we drew attention to supply chain resilience and affordability. We saw that
Like other domains such as taxation, social security and defence, healthcare is one of the least ‘Europeanised’ policy areas in the EU. Member states continue
Last Wednesday, President Ursula von der Leyen announced her plans for the brand-new European Health Response and preparedness Authority (HERA) during her State of the
Lykke Advice is registered in the EU transparency register via this number: 635877723431-08
by Farweb